2015
DOI: 10.1080/19420862.2015.1055443
|View full text |Cite
|
Sign up to set email alerts
|

A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus

Abstract: Sun (2015) A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus, mAbs, 7:5, 969-980, DOI: 10.1080DOI: 10. /19420862.2015 Systemic lupus erythematosus (SLE) is a chronic, heterogeneous autoimmune disease short of effective therapeutic agents. A multitude of studies of SLE in the last decade have accentuated a central role of the interferon alpha (IFN-a) pathway in SLE pathogenesis.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(7 citation statements)
references
References 34 publications
0
7
0
Order By: Relevance
“…Most antibodies inhibited EGFR via binding it, but their epitopes are different [17, 24, 25]. Here, we analyzed Ame55's binding domain with a ForteBio Octet QKe System (Pall ForteBio Corporation, Menlo, CA) as previously described [22]. The results indicated that Ame55 binding to EGFR could be inhibited by EGF in a similar manner to cetuximab and nimotuzumab (Figure 2(a)).…”
Section: Resultsmentioning
confidence: 85%
See 3 more Smart Citations
“…Most antibodies inhibited EGFR via binding it, but their epitopes are different [17, 24, 25]. Here, we analyzed Ame55's binding domain with a ForteBio Octet QKe System (Pall ForteBio Corporation, Menlo, CA) as previously described [22]. The results indicated that Ame55 binding to EGFR could be inhibited by EGF in a similar manner to cetuximab and nimotuzumab (Figure 2(a)).…”
Section: Resultsmentioning
confidence: 85%
“…Of these, 95% shared the same sequence with the #55 clone which was sequenced first. The variable region of light- or heavy-chain genes of the scFv #55 were, respectively, cloned into expression vectors pABL and pABG as previously described by Du et al [22]. The IgG1 of #55 (named Ame55) was expressed in HEK293T cells and purified.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…31 Another monoclonal antibody, AIA22, neutralizes multiple IFN-α subtypes and binds to a novel epitope on IFN-α which binds to the Type II IFN receptor. 32 Its utility in lupus is being further investigated. Anifrolumab is another monoclonal antibody that targets interferon receptor Type I that is being currently investigated in lupus.…”
Section: Agents Directly Targeting Type I Interferonsmentioning
confidence: 99%